A Clinical Trial Looking at the Comparability of 2 Different Forms of Semaglutide
Status:
Recruiting
Trial end date:
2022-06-23
Target enrollment:
Participant gender:
Summary
In this trial, two approved solutions of the medicine semaglutide will be compared in healthy
volunteers. The purpose of this trial is to see if semaglutide B and semaglutide D solutions
are comparable with regards to moving into, through and out of the body when given in two
separate injections. Participants will receive semaglutide B and semaglutide D in different
periods of the trial (Period 1 and Period 2). Participants will receive 1 subcutaneous
injection of semaglutide B (0.5 mg) and 1 subcutaneous injection of semaglutide D (0.5 mg).
The trial will last for 87 to 120 days (about 3 to 4 months), depending on how long the
screening period (2 to 28 days) and washout period (14 to 21 days) are. Participants will
have a screening visit, followed by an in house stay (5 nights/6 days) and 9 visits for each
period. Participants will have to fast for at least 6 hours overnight with only water allowed
before receiving the trial medicine on the second day of in house stay (Day 1) in Period 1
and Period 2.